25912-36-1

Usage

InChI:InChI=1/C11H10N2OS/c14-10-9(7-12-11(15)13-10)6-8-4-2-1-3-5-8/h1-5,7H,6H2,(H2,12,13,14,15)

Upstream product

• 2021-28-5 ethyl dihydrocinnamate 
• 17356-08-0 thiourea 
• 109-94-4 formic acid ethyl ester 
• 124957-36-4 Methyl 3-acetoxy-2-methylene-3-phenylpropanoate 
• 98516-80-4 ethyl 2-formyl-3-phenylpropionate 

Downstream Products

• 18493-83-9 5-benzyluracil 
• 73717-80-3 5-benzyl-2-(methylthio)pyrimidine-4(1H)-one 
• 1359815-24-9 5-benzyl-1-(4-chlorobenzyl)-2-(3-chloro-4-isopropoxyphenylamino)pyrimidine-4(1H)-one 
• 1359818-35-1 5-benzyl-1-(4-chlorobenzyl)-2-(methylthio)pyrimidine-4(1H)-one 
• 116608-81-2 SKF 92693 dihydrochloride 
• 118380-80-6 5-benzyl-1-(2-acetoxyethoxymethyl)uracil 
• 82857-69-0 5-Benzylacyclouridine 

Relevant academic research and scientific papers

New Facile Synthesis of 2-Alkylthiopyrimidin-4(3 H)-ones by Tandem Aza-Wittig Reaction Starting from the Baylis-Hillman Adducts

Iminophosphoranes reacted with CS2 at -5 °C to produce the isothiocyanates, which were treated with primary amine to give thioureas in 73-91% yields. The subsequent reaction of thioureas with alkyl bromides in the presence of solid K2/sub

Heterocyclic derivative and pharmaceutical composition comprising the same

The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compoun

NOVEL HETEROCYCLIC DERIVATIVES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention provides novel compounds having a P2X3 and/or P2X2/3 receptor antagonistic effect. A pharmaceutical composition having a P2X3 and/or P2X2/3 receptor antagonistic effect comprising a compoun

Pyrimidinone compounds

Pyrimidinone compounds of formula (I) are inhibitors of the enzyme Lp-PLA2 and of use in therapy, in particular for treating atherosclerosis.

Inhibition of uridine phosphorylase: Synthesis and structure-activity relationships of aryl-substituted 5-benzyluracils and 1-[(2- hydroxyethoxy)methyl]-5-benzyluracils

A series of 1-[(2-hydroxyethoxy)methyl]-5-benzyluracils were synthesized and tested for inhibition of murine liver uridine phosphorylase (UrdPase). Inhibitors of UrdPase are reported to enhance the chemotherapeutic utility of 5-fluoro-2'-deoxyuridine and 5-fluorouracil and to ameliorate zidovudine- induced anemia in animal models. We prepared a series of 5-aryl-substituted analogues of 5-benzylacyclouridine (BAU), a good inhibitor of UrdPase (IC50 of 0.46 μM), to develop a compound with enhanced potency and improved pharmacokinetics. The first phase of structure-activity relationship studies on a series of 32 aryl-substituted 5-benzyluracils found several 5-(3- alkoxybenzyl) analogues of 5-benzyluracil with enhanced potency. The acyclovir side chain, the (2-hydroxyethoxy)methyl group, was substituted on the more potent aryl-substituted 5-benzyluracils. The two most potent compounds, 10y (3-propoxy) and 10dd (3-sec-butoxy), were inhibitors of UrdPase with IC50s of 0.047 and 0.027 μM, respectively. Six compounds were tested in vivo for effects on steady-state concentrations of circulating uridine in rats. Plasma uridine levels were elevated 3-9-fold by compound levels that ranged from 8 to 50 μM.